E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Major Depressive Disorder (MDD) |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025453 |
E.1.2 | Term | Major depressive disorder NOS |
E.1.2 | System Organ Class | 10037175 - Psychiatric disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of AZD6765iv (50 mg or 100 mg/infusion) as adjunct to current antidepressant medication versus antidepressant medication + placebo as assessed by the change from baseline to Week 6 in the MADRS total score in patients with MDD who exhibited an inadequate response to 3 or more different antidepressant treatments by history. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the efficacy of AZD6765iv (50 mg and 100 mg )as adjunct to current antidepressant medication versus antidepressant medication + placebo in patients with MDD who exhibited an inadequate response to 3 or more different antidepressant treatments by history, as defined by:
•Change from baseline to Week 12 in MADRS total score
• Percentage of patients with sustained response from Week 6 to 12
• Change from baseline in MADRS total score
• Percentage of patients who are responders (defined as a ≥50% reduction from baseline on the MADRS total score)
• Percentage of patients who are remitted (defined as a ≤8 on the MADRS total score)
• Change from baseline in functional impairment as measured by the SDS total score
• Change from baseline in severity of depressive symptoms as measured by Clinical CGI-S
• Improvement of depressive symptoms as measured by CGI-I scale |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Provision of signed and dated informed consent before initiation of any study-related procedures.
2) Male or female patients aged 18 to 70 years, inclusive.
3) The patient must have a clinical diagnosis of major depressive disorder with a lifetime history of inadequate response to at least 3 antidepressants.
4) Women of child-bearing potential must have a negative serum pregnancy test and confirmed use of a highly effective form of birth control before enrollment for a minimum of 3 months before study start.
5) Outpatient status at screening and randomization visits |
|
E.4 | Principal exclusion criteria |
1) Patients with a history of diagnosed bipolar disorder or schizophrenia or schizoaffective disorder or currently exhibiting psychotic features associated with their depression; dementia or suspicion thereof.
2) Patients who have had a suicide attempt within the last 6 months.
3) Electroconvulsive therapy (ECT), vagal nerve stimulation (VNS) or transcranial magnetic stimulation (TMS) or previous treatment with ketamine infusion within the 6 months prior to screening, or any history of deep brain stimulation.
4) Patients with any history of seizure disorder (except for febrile seizures in childhood).
5) Pregnancy or lactation. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To evaluate the efficacy of AZD6765iv (50 mg or 100 mg/infusion) as adjunct to current antidepressant medication versus antidepressant medication + placebo as assessed by the change from baseline to Week 6 in the MADRS total score in patients with MDD who exhibited an inadequate response to 3 or more different antidepressant treatments by history. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Will be scored at Weeks 1 (baseline), 2, 3, 4, 5 and 6 |
|
E.5.2 | Secondary end point(s) |
To evaluate the efficacy of AZD6765iv (50 mg and 100 mg )as adjunct to current antidepressant medication versus antidepressant medication + placebo in patients with MDD who exhibited an inadequate response to 3 or more different antidepressant treatments by history, as defined by:
1) Change from baseline to Week 12 in MADRS total score
2) Percentage of patients with sustained response from Week 6 to 12
3) Change from baseline in MADRS total score
4) Percentage of patients who are responders (defined as a ≥50% reduction from baseline on the MADRS total score)
5) Percentage of patients who are remitted (defined as a ≤8 on the MADRS total score)
6) Change from baseline in functional impairment as measured by the Sheehan Disability Scale (SDS) total score
7) Change from baseline in severity of depressive symptoms as measured by Clinical Global Impression-Severity of Illness (CGI-S) scale
8) Improvement of depressive symptoms as measured by Clinical Global Impression-Improvement (CGI-I) scale
9) Change from baseline in self-rated severity of depressive symptoms at each scheduled assessment as measured by Quick Inventory of Depressive Symptomatology Self-Report 16-item scale (QIDS-SR-16) total score.
10) Adverse events (AEs)/serious adverse events (SAEs), including their severity. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) Will be scored at Weeks 1 (baseline), 2, 3, 4, 5, 6, 8, 10 and 12.
2) same as above
3) Will be scored at Weeks 1 (baseline), 2, 3, 4, 5, 6, 8, 10, 12, 13, 14, 16, 18 and 20
4) same as above
5) same as above
6) Will be scored at Weeks 1 (baseline), 6, 12 and 20
7) Will be scored at Weeks 1 (baseline), 2, 3, 4, 5, 6, 8, 10, 12, 13, 16 and 20.
8) Will be scored at Weeks 2, 3, 4, 5, 6, 8, 10, 12, 13, 16 and 20.
9) Will be scored at Weeks 2, 3, 4, 5, 6, 8, 10, 12, 13, 16 and 20.
10) Will be scored at Weeks 1 (baseline), 3, 6, 12, 16 and 20.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 9 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Chile |
Slovakia |
South Africa |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 0 |